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1. Introduction 
Somatostatin, a cyclic tetradecapeptide, inhibits 
the release of growth hormone from the pituitary and 
glucagon and insulin from the pancreas of fasted mam- 
mals [1,2]. Its value as a therapeutic agent is severely 
limited, however, by its extremely short biological 
half life of approx. 4 min [3, 4]. As in the case of other 
peptidyl hormones there is considerable interest in 
the preparation of longer acting derivatives which 
could have application to the treatment of diabetes 
and developmental disorders. For the preparation of 
synthetic analogs aknowledge of the mechanisms of
inactivation i  brain and tissues could facilitate a
more rational approach as illustrated recently for 
other hypothalamic releasing factors. In the case of 
LH-RH 0uteinising hormone releasing hormone) it 
was shown that a simple substitution of an internal 
residue by D-Ala blocked the action of an endopep- 
tidase with a resultant increase in the biological acti- 
vity in vivo [5]. This particular study introduced a 
new concept, namely, that structure as related to 
biodegradation is equally valid to the traditional ap- 
proach involving considerations of structure-receptor 
relationships. Analogs with improved stability in pre- 
sence of serum or tissue enzymes are more likely to 
reach the target sites involved in hormonal action and 
this may account for their longer action. 
Somatostatin unlike LH-RH is characterised by 
a free N-terminal grouping and by the presence of a 
disulfide bridge spanning residues 3-14 [ 1 ]. As such, 
it is a potential substrate for the action of aminopep- 
tidases present in crude extracts but the role of the 
ring structure in breakdown isunexplored. It has been 
established in the case of other cyclic hormones, not- 
ably oxytocin and vasopressin, that the ring acts as 
a steric hindrance to aminopeptidases and some endo- 
peptidases; these hormones are inactivated in brain, 
however, by novel C-terminal cleaving enzymes act- 
ing on the tripeptidyl alicyclic tails [6,7]. With the 
objective of delineating the enzymes involved in break- 
down of somatostatin, this hormone and its cyclic 
and linear analogs were incubated with crude and par- 
tially purified enzyme from rat brain since these ex- 
tracts are known to contain a spectrum of enzymes 
cleaving a variety of peptidyl hormones [8]. 
2. Materials and methods 
Somatostatin (GH-RIH, growth hormone releas- 
ing hormone) and its cyclic and linear analogs were 
supplied as a gift by Jean Rivier of the Salk Institute, 
San Diego, California. These included the native form 
(fig.l) the reduced form H2 somatostatin (H2 GH- 
RIH), and two analogs des(Ala I -Gly2)-N-acetyl-Cys a 
GH-RIH and des(Ala 1 -Gly 2)-N-acetyl.Cys 3 H2 GH-RIH. 
At the concentrations u ed all were completely solu- 
ble in water or buffer at pH 7.6 
Brain extracts were prepared from the rat by homo- 
genization in 10 vols of cold 0.32 M sucrose contain- 
ing 0.1 mM Cleland's reagent and then centrifuged 
at 100 000 g for 1 hr to prepare the supernatant frac- 
tions. Enzyme was purified batchwise using 10 ml of 
supernatant which was applied to a column of DEAE- 
cellulose 25 × 2 cm equilibrated with a 40 mM Tris- 
HC1 buffer pH 7.6 containing 0.1 mM Cleland's rea- 
gent. Enzyme was eluted stepwise with a salt gradient 
0.1-0.3 M NaC1. All fractions were tested for pro- 
teinase activity with hemoglobin using the method 
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Fig. 1. Amino acid sequence ofsomatostatin (GH-RIH). The arrows indicate probable sites of action of brain neutral proteinase 
based on the release of residues by rat brain extracts after 1 hr incubation (see table 1). 
of Marks et al. [9] and the active fractions then test- 
ed with hormone. Incubations with hormone gener- 
ally consisted of 0.1 ml ofhomogenate ( quivalent 
to 1 mg protein)~r 0.1 ml supernatant (0.3 mg pro- 
tein) or 0.5 ml of the purified enzyme fraction (0.1 mg) 
eluted with 0.1-0.2 M NaC1 from the DEAE-cellulose 
column, to which was added 50 nmol ofhormone 
in a vol of 0.2 mi of water, and 0.1 ml of 40 mM 
Tris-HC1 buffer. The reaction was terminated by ad- 
dition of an equal volume of 6% w/v sulfosalicylic acid 
and then centrifuged at 2 000 g, and the supernatant 
retained. Breakdown was evaluated from the release 
of free amino acids as detected by a modified method 
on the Technicon autoanalyzer aspreviously described 
[8]. It was shown in earlier studies that a large num- 
bre of peptidyl intermediates have low color values re- 
lative to norleucine and do no~ interfere [5-8] .  All 
reactions were carried out in triplicate with suitable 
controls. 
3. Results and discussion 
Incubation of the native form of somatostatin 
with rat brain homogenate or its supernatant fraction 
led to the release within 3 hr at 37°C of all the con- 
stituent amino acids (table 1). The release of the in- 
ternal amino acids (Phe, Lys, Trp, Thr) in larger a- 
mounts as compared to the N- and C-terminal (Ala, 
Gly, Ser and Cys) point to an internal cleavage as a 
rate-limiting step. Crude extracts contain a spectrum 
of enzymes o that there is a secondary release of am- 
ino acids resulting from the action of exopeptidases 
acting on the split fragments. The preferential release 
of internal amino acids by a 'neutral endopeptidase' 
is thus similar to that reported for bradykinin [10], 
LH-RH [5] and substance P [11]. An indication of 
the probable sites for cleavage was provided by a time 
study (table 1). With native somatostatin at 1 hr the 
only amino acids detected were Phe and Lys imply- 
ing that bonds adjacent to these residues were involv- 
ed (fig.l). At 3 hr, all amino acids residues were de- 
tecteu m varying proportions (table 1) with a max- 
imum breakdown of about 40% for the internal resi- 
dues. Based on the appearance of Phe this rate of break- 
down is equivalent to 1.4 #mol per g fresh weight per 
hr. Incubation for longer periods did not significantly 
increase the release of amino acids. This could indicate 
that a number of the intermediate products are poor 
substrates for brain exopeptidases or that the enzyme 
involved is labile. Neutral proteinases of brain are 
known to be labile and the present observations are 
in accordance with previous tudies using LH-RH and 
substance P [5, 11 ]. 
Incubation of the linear (reduced) hormone (H2- 
GH-RIH) with brain supernatant gave a similar pat- 
tern of release xcept for the earlier appearance of Thr 
at 1 hr as compared to the cyclic hormone (table 1). 
This could indicate an additional cleavage site for the 
brain endopeptidase. These data show that the ring 
structure does not play a significant role in rates nf 
breakdown. This result is in striking contrast to oxy- 
tocin, a cyclic nonapeptide which is unaffected by 
crude and purified brain aminopeptidases and endo- 
peptidases: removal of the disulfide bridge, however, 
leads to a very rapid degradation [6, 7]. Although 
somatostatin has a free N-terminal alanine its low 
rate of release at the shorter incubation periods in- 
dicates that this is not a major route of inactivation. 
It is known, however, that the N-terminal dipeptide 
in any case is not essential for biological activety [4]. 
It might be concluded that linear analogs lacking 
AIa-GIy have a greater likelihood for better activity 
in addition to involving simpler synthetic procedures. 
Studies on two of the available analogs upport 
the earlier conclusion for the oresence in brain of a 
221 
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Table 2 
Partial purification of the enzyme inactivating GH-RIH 
Fraction Protein Activity Specific activity Purification 
(mg) (nmoles Phe) (nmoles Phe/mg pr.) 
Homogenate 110 4350 39 1 
Supernatant 23 3700 161 4 
100 000 g 
DEAE- 5 1400 280 7.2 
cellulose 
0.1-0.2 M 
NaC1 
Enzyme was purified batchwise using 10 ml of supernatant prepared in 0.32 M 
sucrose containing 0.1 mM Cleland's reagent as described in the Methods Section. 
Enzyme was applied to a column of DEAE-cellulose 25 X 2 cm equilibrated with 
the same buffer and eluted stepwise with 0.1, 0.2 and 0.3 M of NaC1. Breakdown 
was evaluated from the release of Phe in a 3 hr incubation. 
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rate-limiting endopeptidase. Incubation of the analog 
lacking the N-termmal dipeptide and with a blocked 
Cys at position 3, des(Ala-Gly)-N-acetyl Cys 3 GH- 
RIH, with brain supernatant again led to a preferen- 
tial release of internal amino acids. In this case the 
role of an aminopeptidase in the initial cleavage can 
be completely excluded. Also the poor release of Ser 
would further exclude a major role for carboxypeptid- 
ases acting on the intact hormone. As in the case of 
the intact hormones the absence of a disulfide ring 
in the analog des(Ala-Gly)-N-Cys 3 H2 GH-RIH did not 
significantly alter the release of internal amino aciOs 
relative to those of the N- and C-terminal. These two 
analogs are reported to have a more sustained action 
in vivo [4] but this may be more related to their insol- 
ubility requiring administrations a a suspension lead- 
ing to a sustained release. 
Brain 'neutral endopeptidases' are exremely 
labile and as a consequence have never been adequat- 
ely characterized [ 12]. Partial purification of the 
brain enzyme inactivating somatostatin was achieved 
by passage through a short column of DEAE-cellulose 
as described briefly in the Methods section. The su- 
pernatant was 4-fold and the enzyme luted with 0.1-0.2 
M NaC1 was approx. 7-fold enriched as compared to 
that of  the homogenate. The active fractions were 
characterised by high rates of breakdown when incu- 
bated with protein substrates such as hemoglobin and 
histone. This finding thus supports the contention that 
a neutral proteinase is involved but additional studies 
are required to determine if it is identical to that in- 
activating LH-RH, bradykinin and substance P 
[5,10,111. 
4. Conclusions 
Somatostatin s cleaved by brain extracts with 
the release in varying amounts of all the constituent 
amino acids. The relative rates for release of Phe, Lys, 
Trp and Thr (internal amino acids) to that for Ala, 
Gly, Ser, and Cys (N- and C-terminal) point to the 
acion of a neutral endopeptidase asplaying a rate- 
limiting role. Studies with analogs indicated that the 
presence or absence of a disulfide ring did not signifi- 
cantly alter rates of breakdown. The slower removal 
of Ala at short incubation periods showed that soma- 
tostatin is not a good substrate for brain aminopeptid- 
ases. The lower release of Cys and Ser similarly indi- 
cated that carboxypeptidases do not represent a major 
route for breakdown. Studies with analogs with a 
blocked N-terminal cysteine confirm the mechanism 
for the action of an endopeptidase. The enzyme in- 
volved is labile and has the characteristics a sociated 
with a brain neutral proteinase. These studies indicate 
the need to prepare new derivatives in the linear-form 
having D-amino acids or other substituents at the posi- 
tions of the internal amino acids in order to block the 
rate-limiting sites of reactivation. 
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